CytoDyn Home

CytoDyn, Inc.

In the Newsroom – CytoDyn Explains How Documentary Movies Are Made –

When Cytolin® Came to The Rescue ― as Reported by CBS-TV News

More than just first-in-its-class, Cytolin® is the first antibody designed to help the human immune system regain control of HIV infection with extensive use in humans, only a portion of which is recounted above.You may wonder why it's needed when there are already so many AIDS drugs. But all the other drugs attack HIV directly. In order to survive, the virus has had to develop resistance to those drugs. The Financial Times Reports on the Growing Resistance to Antiretroviral Drugs. Even those who have never taken an antiretroviral drug have drug-resistant strains and standard testing is not sensitive enough to evaluate the problem, according to the latest science news. Furthermore, deaths due to the side effects of antiretroviral drugs are still not fully understood, according to a recent report in U.S. News.

Facts About The Antibody Market

Avastin®, already approved to treat patients with advanced colorectal and advanced non-small cell lung cancer, is Genentech's biggest seller at a hefty $2.3 billion in U.S. sales in 2007.

Erbitux® sales, excluding the United States, rose to $186 million in the fourth quarter from $125.8 million a year earlier, according to ImClone Systems Inc.

The second wave of therapeutic antibody technologies, encompassing optimized full size, fully human antibodies as well as the bits and pieces of individual antibody fragments and alternative binding domains is driving the formation of innovative technology platforms. While biotechs have led the race towards the discovery of novel technologies, big pharma has taken over the reigns for the development of many of these future therapeutic drugs. © 2008 BioMarket Group.

Intellectual Property

The Company also has foreign patent counterparts issued, and patents licensed from a unit of Harvard University for the next generation of products.

Homepage Hits